Nervous System News and Research

Latest Nervous System News and Research

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Trevena prices initial public offering of common stock

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share.

31 Jan 2014

Neuroscientist, researchers receive Vilcek Prize in Biomedical Science

The Vilcek Foundation is pleased to name Thomas M. Jessell as the winner of the 2014 Vilcek Prize in Biomedical Science. Awarded annually, the Vilcek Prizes honor the contributions of immigrants to the American arts and sciences, and include $100,000 cash awards.

30 Jan 2014

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.

30 Jan 2014

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

29 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

The gene therapy-based research project to tackle Friedreich's ataxia launched in November in labs at the Institute for Research in Biomedicine, in Barcelona, and the "Centro de Biolog-a Molecular Severo Ochoa", in Madrid, has received 100,000 US$ per year for two years from the Friedreich's Ataxia Research Alliance.

29 Jan 2014

Johns Hopkins researchers reveal how non-CpG methylation may contribute to Rett Syndrome

In normal development, all cells turn off genes they don’t need, often by attaching a chemical methyl group to the DNA, a process called methylation. Historically, scientists believed methyl groups could only stick to a particular DNA sequence: a cytosine followed by a guanine, called CpG. But in recent years, they have been found on other sequences, and so-called non-CpG methylation has been found in stem cells, and in neurons in the brain.

28 Jan 2014

Study: Nightmares have greater emotional impact than bad dreams do

According to a new study by researchers at the University of Montreal, nightmares have greater emotional impact than bad dreams do, and fear is not always a factor. In fact, it is mostly absent in bad dreams and in a third of nightmares.

28 Jan 2014

Staged surgery for most complex cases of childhood epilepsy

A staged approach to epilepsy surgery-with invasive brain monitoring followed by surgery in a single hospital stay-is a safe and beneficial approach to treatment for complex cases of epilepsy in children, reports the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

28 Jan 2014

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

e-Therapeutics plc today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials.

24 Jan 2014

SCCA Proton Therapy ProCure Center achieves milestone of treating 100 adult and pediatric cancer patients

Past and present patients, families, friends, staff and physicians of SCCA Proton Therapy, A ProCure Center gathered this week to commemorate the milestone of treating 100 adult and pediatric cancer patients.

24 Jan 2014

People with higher levels of omega-3 fatty acids may have larger brain volumes in old age

People with higher levels of the omega-3 fatty acids found in fish oil may also have larger brain volumes in old age equivalent to preserving one to two years of brain health, according to a study published in the January 22, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. Shrinking brain volume is a sign of Alzheimer's disease as well as normal aging.

23 Jan 2014

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

Joint research program in SMA enters initial stage of clinical development

PTC Therapeutics, Inc., the SMA Foundation, and Roche, announced today that their joint research program in Spinal Muscular Atrophy has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers.

22 Jan 2014

People who are less patient tend to move eyes with greater speed, say researchers

Using a simple study of eye movements, Johns Hopkins scientists report evidence that people who are less patient tend to move their eyes with greater speed. The findings, the researchers say, suggest that the weight people give to the passage of time may be a trait consistently used throughout their brains, affecting the speed with which they make movements, as well as the way they make certain decisions.

22 Jan 2014

Study provides new information about life expectancy of people with multiple sclerosis

The first large scale study in the U.S. on the mortality of patients with multiple sclerosis has been published and provides new information about the life expectancy of people with the disease. The study appears in the journal Multiple Sclerosis and Related Disorders.

21 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

Patients with MS could stave off disease symptoms by increasing vitamin D intake

For patients in the early stages of multiple sclerosis (MS), low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a new study led by Harvard School of Public Health (HSPH) investigators in collaboration with Bayer HealthCare.

20 Jan 2014

Nervous System News and Research

Latest Nervous System News and Research

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Trevena prices initial public offering of common stock

Neuroscientist, researchers receive Vilcek Prize in Biomedical Science

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

Johns Hopkins researchers reveal how non-CpG methylation may contribute to Rett Syndrome

Study: Nightmares have greater emotional impact than bad dreams do

Staged surgery for most complex cases of childhood epilepsy

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

SCCA Proton Therapy ProCure Center achieves milestone of treating 100 adult and pediatric cancer patients

People with higher levels of omega-3 fatty acids may have larger brain volumes in old age

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

Joint research program in SMA enters initial stage of clinical development

People who are less patient tend to move eyes with greater speed, say researchers

Study provides new information about life expectancy of people with multiple sclerosis

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Patients with MS could stave off disease symptoms by increasing vitamin D intake

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Nervous System News and Research

Latest Nervous System News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in